Citations

Clear

9383 citation(s) found for "Thomas, PS".

Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant
Warsame, Rahma , Kumar, Shaji , Lacy, Martha Q. , Dingli, David , Hayman, Suzanne R. , Kapoor, Prashant , Kyle, Robert A. , Leung, Nelson , Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Dispenzieri, Angela , Bang, Soo‐Mee , Gertz, Morie A. , Buadi, Francis K. , Witzig, Thomas E. , Rajkumar, S. Vincent , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David

Mayo Clinic

European Journal of Haematology | February 6, 2014 | Volume: 92 | Issue: 6 | Pages: 485-490

10.1111/ejh.12282 | PMID 24502602 Get It

AbstractImmunoglobulin light chain (AL) Amyloidosis is a condition whereby misfolded proteins generated by plasma cells deposit in tissues causing organ dysfunction. Chemotherapy and autologous stem cell transplant when eligible are standard treatment options. Several studies report long‐term outcomes of patients post‐transplant. However, there is a paucity of literature describing outcomes of relapsed patients post‐transplant. We performed a retrospective study to assess outcomes and therapies employed upon relapse after transplant. Between 1996 and 2009, 410 patients received transplant at the Mayo Clinic as first‐line therapy. Of those patients, 42 (10%) died within 3 months of transplant, 64 (16%) died without documented relapse, 158 (38%) were alive without documented progression, and 146 (36%) had documented progression. Those 146 patients are the subject of our study, and their median time to hematologic relapse/progression was 23.6 months (95%CI 18.3, 26.3 months). Their median overall survival and 5‐yrs overall survival from post‐transplant relapse/progression was 51.7 months (95%CI 34.1–62.3) and 39%, respectively. The most common first regimen for treatment after relapse was lenalidomide or thalidomide. In conclusion, our study indicates that patients with AL amyloidosis fare well post‐transplant relapse/progression. Additionally, it provides a yardstick to design clinical trials to determine best treatment options.
Bone loss management in revision total knee arthroplasty
Martino, Ivan De , Sakellariou, Vasileios I. , Sculco, Peter K. , Poultsides, Lazaros, Sculco, Thomas P.

Mayo Clinic

Current Advances in Total Knee Arthroplasty | February 6, 2014 | Volume: No volume available | Issue: No issue available | Pages: 68-79

10.2217/fmeb2013.13.247 Get It

GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features
Feldman, Andrew L. , Wada, David A., Lu, Ye , Polk, Avery , Briski, Robert , Ristow, Kay M., Ziesmer, Steven C., Wellik, Linda, Lanigan, Thomas M. , Pittelkow, Mark R. , Bailey, Nathanael G. , Hristov, Alexandra C. , Lim, Megan S. , Ansell, Stephen M. , Wang, Tianjiao , Habermann, Thomas M. , Thomas, Dafydd G. , Witzig, Thomas E. , Wilcox, Ryan A. , Feldman, Andrew L , Lim, Megan S

Mayo Clinic

Blood | February 5, 2014 | Volume: 123 | Issue: 19 | Pages: 3007-3015

10.1182/blood-2013-12-544809 | PMID 24497534 Get It

Key Points Alternatively polarized macrophages are abundant constituents of the tumor microenvironment in T-cell lymphoproliferative disorders. GATA-3 expression identifies a subset of PTCL, NOS with a distinct cytokine profile and inferior survival.
MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma
Jones, E. Ellen , Powers, Thomas W. , Neely, Benjamin A. , Cazares, Lisa H. , Parker, Alexander S. , Troyer, Dean A. , Drake, Richard R.

Mayo Clinic

PROTEOMICS | February 4, 2014 | Volume: 14 | Issue: 7-8 | Pages: 924-935

10.1002/pmic.201300434 | PMID 24497498 Get It

Reducing the incidence and mortality rates for clear cell renal cell carcinoma (ccRCC) remains a significant clinical challenge with poor 5‐year survival rates. A unique tissue cohort was assembled of matched ccRCC and distal nontumor tissues (n = 20) associated with moderate risk of disease progression, half of these from individuals who progressed to metastatic disease and the other half who remained disease free. These tissues were used for MALDI imaging MS profiling of proteins in the 2–20 kDa range, resulting in a panel of 108 proteins that had potential disease‐specific expression patterns. Protein lysates from the same tissues were analyzed by MS/MS, resulting in identification of 56 proteins of less than 20 kDa molecular weight. The same tissues were also used for global lipid profiling analysis by MALDI‐FT‐ICR MS. From the cumulative protein and lipid expression profile data, a refined panel of 26 proteins and 39 lipid species was identified that could either distinguish tumor from nontumor tissues, or tissues from recurrent disease progressors from nonrecurrent disease individuals. This approach has the potential to not only improve prognostic assessment and enhance postoperative surveillance, but also to inform on the underlying biology of ccRCC progression.
p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis
Zhong, Jian , Ding, Liya , Bohrer, Laura R., Pan, Yunqian , Liu, Ping , Sebo, Thomas J., Karnes, R. Jeffrey , Tindall, Donald J., Deursen, Jan van, van Deursen, Jan, Zhang, Jun , Huang, Haojie

Mayo Clinic

Cancer Research | January 30, 2014 | Volume: 74 | Issue: 6 | Pages: 1870-1880

10.1158/0008-5472.can-13-2485 | PMID 24480624 Get It

Abstract Overexpression of the histone acetyltransferase p300 is implicated in the proliferation and progression of prostate cancer, but evidence of a causal role is lacking. In this study, we provide genetic evidence that this generic transcriptional coactivator functions as a positive modifier of prostate tumorigenesis. In a mouse model of PTEN deletion–induced prostate cancer, genetic ablation of p300 attenuated expression of the androgen receptor (AR). This finding was confirmed in human prostate cancer cells in which PTEN expression was abolished by RNA interference–mediated attenuation. These results were consistent with clinical evidence that the expression of p300 and AR correlates positively in human prostate cancer specimens. Mechanistically, PTEN inactivation increased AR phosphorylation at serine 81 (Ser81) to promote p300 binding and acetylation of AR, thereby precluding its polyubiquitination and degradation. In support of these findings, in PTEN-deficient prostate cancer in the mouse, we found that p300 was crucial for AR target gene expression. Taken together, our work identifies p300 as a molecular determinant of AR degradation and highlights p300 as a candidate target to manage prostate cancer, especially in cases marked by PTEN loss. Cancer Res; 74(6); 1870–80. ©2014 AACR.
Is rituximab one for all ages and each sex?
Habermann, Thomas M.

Mayo Clinic

Blood | January 30, 2014 | Volume: 123 | Issue: 5 | Pages: 602-603

10.1182/blood-2013-12-543314 | PMID 24482494 Get It

Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome
Charbonneau, Bridget, Moysich, Kirsten B., Kalli, Kimberly R., Oberg, Ann L. , Vierkant, Robert A. , Fogarty, Zachary C. , Block, Matthew S. , Goergen, Krista M., Cunningham, Julie M. , Rider, David N., Hartmann, Lynn C. , Lawrenson, Kate , Wang, Chen , Song, Honglin , DeFazio, Anna , Johnatty, Sharon E., Phelan, Catherine M., Sellers, Thomas A. , Ramirez, Starr M., Vitonis, Allison F., Terry, Kathryn L. , Pike, Malcolm C. , Wu, Anna H. , Ramus, Susan J. , Diergaarde, Brenda , Shen, Howard C., Jensen, Allan , Menkiszak, Janusz , Lubiński, Jan , Rothstein, Joseph H. , McGuire, Valerie , Sieh, Weiva , Lester, Jenny, Walsh, Christine , Vergote, Ignace , Lambrechts, Sandrina, Despierre, Evelyn, García‐Closas, Montserrat , Brinton, Louise A. , Śpiewankiewicz, Beata, Rzepecka, Iwona K. , Dansonka‐Mieszkowska, Agnieszka , Paddock, Lisa E. , Orlow, Irene , Lundvall, Lene, Olson, Sara H. , Høgdall, Claus , Schwaab, Ira, Harter, Philipp , Flanagan, James M. , Brown, Robert , Ekici, Arif B. , Beckmann, Matthias W. , Hein, Alexander , Eccles, Diana , Lurie, Galina, Hays, Laura E., Bean, Yukie T., Goodman, Marc T. , Campbell, Ian , Fasching, Peter A. , Konecny, Gottfried E. , Kaye, Stanley B., Heitz, Florian , Høgdall, Estrid , Chang‐Claude, Jenny , Kupryjańczyk, Jolanta , Wentzensen, Nicolas , Lambrechts, Diether , Whittemore, Alice S. , Culver, Hoda Anton, Levine, Douglas A. , Kjær, Susanne K. , Menon, Usha , Schildkraut, Joellen M. , Pearce, Celeste Leigh, Rossing, Mary Anne, Chenevix‐Trench, Georgia , group, for the AOCS, ACS, Gayther, Simon A. , Ness, Roberta B., Odunsi, Kunle , Sucheston, Lara E., Knutson, Keith L. , Goode, Ellen L. , Lambrechts, Diether , Maurer, Matthew J. , Fridley, Brooke L. , Preston, Claudia C. , Tyrer, Jonathan P. , Doherty, Jennifer A. , Berg, David Van Den , Berchuck, Andrew , Gentry‐Maharaj, Aleksandra , Cybulski, Cezary , Ziogas, Argyrios , Yang, Hannah , Seibold, Petra , Rudolph, Anja , Bois, Andreas du , Paul, James , Pejovic, Tanja B. , Bandera, Elisa V. , Karlan, Beth Y. , Gronwald, Jacek , Cramer, Daniel W. , group, for the AOCS, ACS, Pharoah, Paul D.P. , Knutson, Keith L. , Fazio, Anna de , Lambrechts, Diether , Kjaer, Susanne K , Ramus, Susan J , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Lawrenson, Kate , Moysich, Kirsten , Orlow, Irene , Wang, Chen , Campbell, Ian G , Menkiszak, Janusz , Brown, Robert , Fogarty, Zachary C , Flanagan, James M , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , García-Closas, Montserrat , Ekici, Arif B , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Diergaarde, Brenda , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Cancer Immunology Research | January 27, 2014 | Volume: 2 | Issue: 4 | Pages: 332-340

10.1158/2326-6066.cir-13-0136 | PMID 24764580 Get It

Abstract The presence of regulatory T cells (Treg) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag single-nucleotide polymorphisms (SNP) in 25 Treg-associated genes (CD28, CTLA4, FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, IL23A, IL23R, IL2RA, IL6, IL6R, IL8, LGALS1, LGALS9, MAP3K8, STAT5A, STAT5B, TGFB1, TGFB2, TGFB3, TGFBR1, TGRBR2, and TGFBR3) in relation to ovarian cancer survival. We analyzed genotype and overall survival in 10,084 women with invasive epithelial ovarian cancer, including 5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous carcinoma cases of European descent across 28 studies from the Ovarian Cancer Association Consortium (OCAC). The strongest associations were found for endometrioid carcinoma and IL2RA SNPs rs11256497 [HR, 1.42; 95% confidence interval (CI), 1.22–1.64; P = 5.7 × 10−6], rs791587 (HR, 1.36; 95% CI, 1.17–1.57; P = 6.2 × 10−5), rs2476491 (HR, = 1.40; 95% CI, 1.19–1.64; P = 5.6 × 10−5), and rs10795763 (HR, 1.35; 95% CI, 1.17–1.57; P = 7.9 × 10−5), and for clear cell carcinoma and CTLA4 SNP rs231775 (HR, 0.67; 95% CI, 0.54–0.82; P = 9.3 × 10−5) after adjustment for age, study site, population stratification, stage, grade, and oral contraceptive use. The rs231775 allele associated with improved survival in our study also results in an amino acid change in CTLA4 and previously has been reported to be associated with autoimmune conditions. Thus, we found evidence that SNPs in genes related to Tregs seem to play a role in ovarian cancer survival, particularly in patients with clear cell and endometrioid epithelial ovarian cancer. Cancer Immunol Res; 2(4); 332–40. ©2014 AACR.
A multicentre study of primary breast diffuse large B‐cell lymphoma in the rituximab era
Hosein, Peter J. , Maragulia, Jocelyn, Salzberg, Matthew, Press, Oliver W. , Bast, Martin, Advani, Ranjana H. , Tibshirani, Robert , Evens, Andrew M. , Islam, Nahida , Leonard, John P. , Martin, Peter , Lossos, Izidore S. , Habermann, Thomas M. , Vose, Julie M. , Zelenetz, Andrew D. , Press, Oliver , Advani, Ranjana H , Evens, Andrew M

Mayo Clinic

British Journal of Haematology | January 27, 2014 | Volume: 165 | Issue: 3 | Pages: 358-363

10.1111/bjh.12753 | PMID 24467658 Get It

SummaryPrimary breast diffuse large B‐cell lymphoma (DLBCL) is a rare subtype of non‐Hodgkin lymphoma (NHL) with limited data on pathology and outcome. A multicentre retrospective study was undertaken to determine prognostic factors and the incidence of central nervous system (CNS) relapses. Data was retrospectively collected on patients from 8 US academic centres. Only patients with stage I/II disease (involvement of breast and localized lymph nodes) were included. Histologies apart from primary DLBCL were excluded. Between 1992 and 2012, 76 patients met the eligibility criteria. Most patients (86%) received chemotherapy, and 69% received immunochemotherapy with rituximab; 65% received radiation therapy and 9% received prophylactic CNS chemotherapy. After a median follow‐up of 4·5 years (range 0·6–20·6 years), the Kaplan–Meier estimated median progression‐free survival was 10·4 years (95% confidence interval [CI] 5·8–14·9 years), and the median overall survival was 14·6 years (95% CI 10·2–19 years). Twelve patients (16%) had CNS relapse. A low stage‐modified International Prognostic Index (IPI) was associated with longer overall survival. Rituximab use was not associated with a survival advantage. Primary breast DLBCL has a high rate of CNS relapse. The stage‐modified IPI score is associated with survival.
Abstract PR-03: Aspirin mediated downregulation of Warburg kinase AKT1 in patients with Barrett's esophagus: Implications in neoplastic transformation
Buttar, Navtej , DeMars, Cathrine J., Chowdhury, Sonia , Elebiary, Ahmed, Sharma, Anamay N. , Chaudhry, Sidhartha, Foster, Nathan R. , Ziegler, Katie L. Allen, Romero, Yvonne , Marcon, Norman E. , Schnell, Thomas , Corley, Douglas A. , Fleischer, David E., Chak, Amitabh , DeVault, Kenneth R. , Weinberg, David S. , Della’Zanna, Gary , Smyrk, Thomas C. , Mandrekar, Sumithra J. , Falk, Gary W. , Sharma, Prateek , Cruz‐Correa, Marcia , Hur, Chin , Richmond, Ellen S. , Limburg, Paul J.

Mayo Clinic

Cancer Prevention Research | January 23, 2014 | Volume: 5 | Issue: 11_Supplement | Pages: PR-03-PR-03

10.1158/1940-6207.prev-12-pr-03 Get It

Abstract Background: In patients with Barrett's esophagus, chronic reflux injury and inflammation are associated with esophageal adenocarcinoma, one of the most rapidly increasing lethal cancers. Epidemiological and preclinical studies support decreased risk of esophageal adenocarcinoma with NSAID use. Gastroesophageal refluxate contents can promote carcinogenesis in Barrett's metaplasia by activating AKT, which up regulates COX-2 expression and prostaglandin biosynthesis. We recently noted that neoplastic transformation in Barrett's esophagus is associated with increased AKT expression, particularly isoform AKT1. The AIM of this study is to investigate the effect of NSAID (Aspirin) use in patients with Barrett's esophagus on AKT1 expression using frozen tissue from the randomized, phase II trial of aspirin and esomeprazole for esophageal cancer chemoprevention in Barrett's esophagus patients and to assess the functional consequences of AKT1 expression in-vitro. Methods and Results: In a subset of patients (12 of 120 patients) with Barrett's esophagus who were randomized to placebo, lower dose (81 mg) or higher dose (325 mg) Aspirin for 4 weeks, both PCR and Western blot revealed marked reduction in AKT1 expression in patients who received 325 mg of Aspirin daily compared to patients who received placebo. Our in-vitro experiments support that AKT1 expression is functionally relevant to the process of carcinogenesis in Barrett's epithelial cells. Using adenovirus to induce AKT1 expression, we show that increased AKT1 expression increases Barrett's epithelial cell growth, facilitates RAS-mediated transformation of pre-neoplastic epithelial cells and promotes colony formation. Since AKT1 is known as Warburg kinase and regulates cellular glucose uptake to support aerobic glycolysis during growth de-regulation and neoplasia, we examined the uptake of fluorescent deoxyglucose analog (2-NBDG) in Barrett's epithelial cells transduced with AKT1 adenovirus. At 48 hrs, compared to control, AKT1 overexpression resulted in increased glucose uptake both by metaplastic and neoplastic Barrett's epithelial cells. Transcriptional repression of AKT1 abrogated the 2-NBDG uptake by these cells. Finally, we did pathway specific qPCRs and noted that use of Aspirin is associated with altered expression of chromatin remodelers that could down-regulate AKT1 expression. Conclusion: Collectively, our results demonstrate that Aspirin mediated down-regulation of Warburg kinase AKT1 in patients with Barrett?s esophagus is a novel mechanism for the regulation of Barrett?s epithelial cell growth. The in-depth characterization of molecular mechanisms is currently underway. This abstract is also presented as Poster A82. Citation Format: Navtej S. Buttar, Gary W. Falk, Cathrine J. DeMars, Sonia Chowdhury, Ahmed Elebiary, Anamay Sharma, Sidhartha Chaudhry, Nathan R. Foster, Katie L. Allen Ziegler, Yvonne Romero, Norman E. Marcon, Thomas Schnell, Douglas A. Corley, Prateek Sharma, Marcia R. Cruz-Correa, Chin Hur, David E. Fleischer, Amitabh Chak, Kenneth R. DeVault, David S. Weinberg, Gary Della’Zanna, Ellen Richmond, Thomas C. Smyrk, Sumithra Mandrekar, Paul J. Limburg. Aspirin mediated downregulation of Warburg kinase AKT1 in patients with Barrett's esophagus: Implications in neoplastic transformation. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr PR-03.